Semaglutide Oral

From Aaushi
Jump to navigation Jump to search

Introduction

see semaglutide

Indications

Dosage

More general terms

References

  1. 1.0 1.1 Husain M, Birkenfeld AL, Donsmark M et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019 Jun 11 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31185157 https://www.nejm.org/doi/10.1056/NEJMoa1901118
  2. 2.0 2.1 Tucker ME FDA OKs 'Game-Changer' Oral GLP-1 Agonist for Type 2 Diabetes. Medscape - Sep 20, 2019. https://www.medscape.com/viewarticle/918772
  3. 3.0 3.1 Aroda VR et al. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): A multicentre, randomised, phase 3b trial. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37385279 Lancet 2023 Jun 25; [e-pub]. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01127-3/fulltext
    Knop FK et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023 Jun 25; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/37385278 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01185-6/fulltext